Sunshine Biopharma Inc.
2.83
0.01 (0.35%)
At close: Jan 15, 2025, 3:17 PM

Company Description

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs.

The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.

It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements.

The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4.

Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

Sunshine Biopharma Inc.
Sunshine Biopharma Inc. logo
Country CA
IPO Date Feb 15, 2022
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 44
CEO Dr. Steve N. Slilaty Ph.D.

Contact Details

Address:
6500 Trans-Canada Highway
Pointe-Claire, QC
CA
Website https://www.sunshinebiopharma.com

Stock Details

Ticker Symbol SBFM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001402328
CUSIP Number 867781304
ISIN Number US8677814035
Employer ID 20-5566275
SIC Code 8731

Key Executives

Name Position
Dr. Steve N. Slilaty Ph.D. Chairman, President & Chief Executive Officer
Camille Sebaaly Chief Financial Officer & Secretary
Dr. Abderrazzak Merzouki Chief Science Officer & Director
Malek Chamoun Chief Development Officer
Robert G. Ferreira President of Sunshine Bio Investments Inc

Latest SEC Filings

Date Type Title
Jan 06, 2025 S-3 Filing
Dec 10, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 424B4 Filing
Nov 07, 2024 8-K Current Report
Nov 06, 2024 POS AM Filing
Nov 05, 2024 10-Q Quarterly Report
Oct 23, 2024 8-K Current Report
Oct 17, 2024 DEF 14A Filing
Sep 10, 2024 8-K Current Report